Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-004122-70-GB
EUCTR2005-004122-70-GB
Active, not recruiting
Phase 1

Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasia

Great Ormond Street Hospital0 sites30 target enrollmentSeptember 12, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsPrevenar

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Great Ormond Street Hospital
Enrollment
30
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 12, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Great Ormond Street Hospital

Eligibility Criteria

Inclusion Criteria

  • •1\.Genetically confirmed diagnosis of AT
  • •2\.Patient/Parental informed consent obtained (and assent from appropriately aged children)
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •1\.Patients \<2 years old
  • •2\.Consent/ assent not given
  • •3\.Patient receiving immunoglobulin therapy (around 12% of patients)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Inmunogenicity-PCV-Carriage-Venezuelan High Risk ChildreInfection Prophylaxis of Streptococcus pneumoniae
RPCEC00000150Servicio Autónomo Instituto de Biomedicina110
Active, not recruiting
Not Applicable
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly18 years old or older volunteers with general good health
EUCTR2012-003484-22-FIHelsinki University Central Hospital600
Active, not recruiting
Not Applicable
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly
EUCTR2012-003484-22-SEHelsinki University Central Hospital300
Not yet recruiting
Not Applicable
Efficacy of pneumococcal conjugate vaccine in preventing acquisition and carriage of pneumococcal vaccine serotypes in Tanzanian children with human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS)Pneumococcal diseaseHIV/AIDSPublic Health - EpidemiologyInfection - Studies of infection and infectious agents
ACTRN12610000999033Prof Robert Booy216
Active, not recruiting
Not Applicable
Immunogenicity of pneumococcal vaccination after prime boosting in HIV-Infected Adults: A Randomised Controlled TrialThe primary objectives of this study are to:1.Prospectively evaluate immunological response to vaccination with the 23-valent polysaccharide vaccine (PPV23) in HIV infected patients over a one year period.2.Evaluate whether a strategy combining a prime with the 13-valent conjugate pneumococcal vaccine (PCV) followed by a boost with the PPV23 would improve immunogenicity against Streptococcus Pneumoniae Polysaccharides (SPP) in HIV-infected patients.
EUCTR2011-000260-99-IEDepartment of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8150